论文部分内容阅读
目的观察阿格列汀与门冬胰岛素30注射液联用治疗2型糖尿病的临床效果。方法选择医院收治的2型糖尿病患者56例,按照治疗方法不同分为对照组和观察组,每组28例。对照组采用门冬胰岛素30注射液治疗,观察组采用阿格列汀联合门冬胰岛素30注射液治疗,观察比较2组的治疗效果及不良反应发生情况。结果观察组治疗总有效率为89.29%,高于对照组的75.00%(P<0.05);观察组不良反应发生率为10.71%,低于对照组的25.00%(P<0.05)。结论阿格列汀与门冬胰岛素30注射液联合治疗2型糖尿病临床效果显著,安全性高,值得临床推广。
Objective To observe the clinical efficacy of alogliptin combined with aspart insulin 30 in the treatment of type 2 diabetes mellitus. Methods 56 cases of type 2 diabetes patients admitted to hospital were divided into control group and observation group according to different treatment methods, with 28 cases in each group. The control group was treated with insulin aspart 30 injection. The observation group was treated with alogliptin plus insulin aspart 30 injection. The therapeutic effects and adverse reactions of the two groups were observed and compared. Results The total effective rate in the observation group was 89.29%, higher than that in the control group (75.00%, P <0.05). The adverse reaction rate in the observation group was 10.71%, which was lower than that in the control group (25.00%, P <0.05). Conclusions The combination of alogliptin and insulin aspart 30 injection in the treatment of type 2 diabetes has significant clinical effect, high safety and worthy of clinical promotion.